| __timestamp | Biogen Inc. | Genmab A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 2232342000 | 79529000 |
| Thursday, January 1, 2015 | 2113100000 | 91224000 |
| Friday, January 1, 2016 | 1947900000 | 102413000 |
| Sunday, January 1, 2017 | 1935500000 | 146987000 |
| Monday, January 1, 2018 | 2106300000 | 213695000 |
| Tuesday, January 1, 2019 | 2374700000 | 342000000 |
| Wednesday, January 1, 2020 | 2504500000 | 661000000 |
| Friday, January 1, 2021 | 2674300000 | 1283000000 |
| Saturday, January 1, 2022 | 2403600000 | 2676000000 |
| Sunday, January 1, 2023 | 2549700000 | 3297000000 |
Igniting the spark of knowledge
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Biogen Inc. and Genmab A/S have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Biogen's SG&A expenses have seen a steady increase, peaking in 2021 with a 38% rise from 2014. Meanwhile, Genmab A/S has experienced a dramatic surge, with expenses skyrocketing by over 4,000% during the same period, reflecting its aggressive expansion and market penetration strategies. Notably, in 2023, Genmab's SG&A expenses surpassed Biogen's, highlighting a pivotal shift in their financial dynamics. This data not only underscores the evolving strategies of these biotech giants but also offers insights into their future market positioning.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Biogen Inc.
SG&A Efficiency Analysis: Comparing Novartis AG and Biogen Inc.
Zoetis Inc. and Genmab A/S: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Biogen Inc.
Biogen Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
Biogen Inc. and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Biogen Inc. or Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Genmab A/S or Cytokinetics, Incorporated
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated